Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Hold” by Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has earned an average rating of “Hold” from the ten research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $9.33.

Several equities analysts have recently issued reports on the company. Royal Bank of Canada cut Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their target price for the company from $15.00 to $4.00 in a research note on Thursday, September 12th. Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Bank of America lowered shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $10.00 to $2.00 in a research note on Thursday, September 12th. Leerink Partners reissued a “market perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Finally, HC Wainwright cut Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $17.00 to $4.00 in a research report on Friday, September 13th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. National Bank of Canada FI raised its stake in Fulcrum Therapeutics by 869.6% during the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after buying an additional 4,000 shares during the last quarter. Capstone Investment Advisors LLC purchased a new position in shares of Fulcrum Therapeutics in the fourth quarter worth $68,000. Profund Advisors LLC bought a new position in shares of Fulcrum Therapeutics during the 2nd quarter valued at about $68,000. Renaissance Technologies LLC purchased a new position in Fulcrum Therapeutics during the 2nd quarter valued at approximately $82,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Fulcrum Therapeutics by 66.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock worth $112,000 after purchasing an additional 4,766 shares during the last quarter. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Down 5.3 %

Shares of NASDAQ FULC opened at $3.57 on Tuesday. The company has a market cap of $221.89 million, a price-to-earnings ratio of -2.23 and a beta of 2.23. The firm’s fifty day moving average is $7.46 and its 200 day moving average is $7.66. Fulcrum Therapeutics has a 52 week low of $2.87 and a 52 week high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Wednesday, July 31st. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.93. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 8.28%. The company had revenue of $80.00 million during the quarter, compared to analyst estimates of $80.00 million. During the same period in the prior year, the business posted ($0.38) earnings per share. Equities research analysts anticipate that Fulcrum Therapeutics will post -0.28 earnings per share for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.